Empower Pharma, Houston, TX

Is Empower Pharma registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Empower Pharma in Houston, TX, first registered Jul 16, 2016 and most recently registered Oct 13, 2026.

Does Empower Pharma hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.

Has Empower Pharma had a state board action or FDA letter?

FDA letters: no matching record found. No entry for Empower Pharma was matched by name and location on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Empower Pharma
Location
Houston, TX
Type as FDA labels it
503B
FDA 503B list
Listed as Empower Pharma
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
None listed
FDA Data Dashboard inspections
No matching site found
State board records
No exact match

FDA inspections and letters

No entry for this name and location was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). That page covers actions from 2019 on; FDA keeps earlier ones in its archive.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

FDA’s 503B list

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 4 products naming semaglutide and tirzepatide under the labeler name “Empower Pharma”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
72627-2321Semaglutide/CyanocobalaminSemaglutide/CyanocobalaminINJECTIONSUBCUTANEOUS.5 mg/1 mL; 1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs
72627-2322Semaglutide/CyanocobalaminSemaglutide/CyanocobalaminINJECTIONSUBCUTANEOUS5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs
72627-2323Tirzepatide/NiacinamideTirzepatide/NiacinamideINJECTIONSUBCUTANEOUS8 mg/1 mL; 2 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs
72627-2324Tirzepatide/NiacinamideTirzepatide/NiacinamideINJECTIONSUBCUTANEOUS2 mg/1 mL; 17 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.